MTNB Stock Overview
A clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Matinas BioPharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.63 |
| 52 Week High | US$21.50 |
| 52 Week Low | US$0.50 |
| Beta | 1.73 |
| 11 Month Change | -80.49% |
| 3 Month Change | -86.41% |
| 1 Year Change | -93.82% |
| 33 Year Change | -98.79% |
| 5 Year Change | -99.07% |
| Change since IPO | -99.02% |
Recent News & Updates
Shareholder Returns
| MTNB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.2% | 4.0% | 2.0% |
| 1Y | -93.8% | 18.0% | 32.4% |
Return vs Industry: MTNB underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: MTNB underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| MTNB volatility | |
|---|---|
| MTNB Average Weekly Movement | 26.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MTNB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MTNB's weekly volatility has increased from 18% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 32 | Jerry Jabbour | www.matinasbiopharma.com |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
Matinas BioPharma Holdings, Inc. Fundamentals Summary
| MTNB fundamental statistics | |
|---|---|
| Market cap | US$3.01m |
| Earnings (TTM) | -US$21.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs MTNB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MTNB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$12.72m |
| Gross Profit | -US$12.72m |
| Other Expenses | US$8.41m |
| Earnings | -US$21.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MTNB perform over the long term?
See historical performance and comparison